WO2006099543A3 - Methods for assessing antibody-mediated cytotoxicity - Google Patents

Methods for assessing antibody-mediated cytotoxicity Download PDF

Info

Publication number
WO2006099543A3
WO2006099543A3 PCT/US2006/009545 US2006009545W WO2006099543A3 WO 2006099543 A3 WO2006099543 A3 WO 2006099543A3 US 2006009545 W US2006009545 W US 2006009545W WO 2006099543 A3 WO2006099543 A3 WO 2006099543A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mediated cytotoxicity
assessing antibody
present
kits
Prior art date
Application number
PCT/US2006/009545
Other languages
French (fr)
Other versions
WO2006099543A2 (en
Inventor
Claude P Genain
D Epinay Patrice H Lalive
Original Assignee
Univ California
Claude P Genain
D Epinay Patrice H Lalive
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Claude P Genain, D Epinay Patrice H Lalive filed Critical Univ California
Publication of WO2006099543A2 publication Critical patent/WO2006099543A2/en
Publication of WO2006099543A3 publication Critical patent/WO2006099543A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to methods and kits for the prognosis and diagnosis of autoimmune diseases. In particular, the present invention provides methods and kits suitable for measuring the neuronal toxicity of biological samples from subjects suspected of having a neurodegenerative disease, such as multiple sclerosis.
PCT/US2006/009545 2005-03-15 2006-03-15 Methods for assessing antibody-mediated cytotoxicity WO2006099543A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66218705P 2005-03-15 2005-03-15
US60/662,187 2005-03-15

Publications (2)

Publication Number Publication Date
WO2006099543A2 WO2006099543A2 (en) 2006-09-21
WO2006099543A3 true WO2006099543A3 (en) 2007-06-28

Family

ID=36992438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/009545 WO2006099543A2 (en) 2005-03-15 2006-03-15 Methods for assessing antibody-mediated cytotoxicity

Country Status (1)

Country Link
WO (1) WO2006099543A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
CN107389628A (en) * 2017-06-09 2017-11-24 福建医科大学孟超肝胆医院 A kind of double-colored detection of Apoptosis and image probe and its application

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105348387B (en) 2010-08-14 2020-08-25 Abbvie 公司 Amyloid beta binding proteins
JP2015512036A (en) * 2012-02-15 2015-04-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Means and methods for assessing neurotoxicity
CN110736828A (en) * 2019-10-18 2020-01-31 南通大学 Function of OPTN mutation-induced OPTN ubiquitination degradation abnormality in neuronal damage and verification method thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIELEKOVA B, MARTIN R.: "Development of biomarkers in multiple sclerosis", BRAIN, vol. 127, no. 7, 2004, pages 1463 - 1478, XP003014845 *
D'ANDREA M.R.: "Add Alzheimer's disease to the list of autoimmune diseases", MEDICAL HYPOTHESIS, vol. 64, no. 3, 2005, pages 458 - 463, XP004691092 *
GALLO P, RINALDI L.: "Immunological markers in multiple sclerosis: tackling the missing elements", NEUROL. SCI., vol. 26, no. 4, 2005, pages S215 - S217, XP019361706 *
LILY O. ET AL.: "Serum autoantobodies to cell surface determinants in multiple sclerosis: a flow cytometric study", BRAIN, vol. 127, no. 2, 2004, pages 269 - 279, XP003014847 *
LU ET AL., J. IMMUNOL., vol. 99, 1999, pages 72 - 81 *
MICOUD F. ET AL.: "Comparison of several techniques for the detection of apoptotic astrocytes in vitro", CELL PROLIF., vol. 34, 2001, pages 99 - 113, XP003014848 *
RUS H. ET AL., ANN MED., vol. 37, 2005, pages 97 - 104 *
ZHOU L, MILLER R.H.: "Antibody-Mediated Oligodendrocyte Cell Death Requires an Astrocyte-Derived Cosignal", J. NEUROSCI. RES., vol. 52, 1998, pages 137 - 148, XP003014846 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN107389628A (en) * 2017-06-09 2017-11-24 福建医科大学孟超肝胆医院 A kind of double-colored detection of Apoptosis and image probe and its application
CN107389628B (en) * 2017-06-09 2019-09-24 福建医科大学孟超肝胆医院(福州市传染病医院) A kind of Apoptosis is double-colored to be detected and image probe and its application

Also Published As

Publication number Publication date
WO2006099543A2 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
WO2006099543A3 (en) Methods for assessing antibody-mediated cytotoxicity
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2006134390A3 (en) Method for diagnosing neurodegenerative disease
WO2006086242A3 (en) Mild osteoarthritis biomarkers and uses thereof
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2007149985A3 (en) Assessing dementia and dementia-type disorders
WO2011064225A8 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
WO2007035651A3 (en) Systemic lupus erythematosus diagnostic assay
WO2007030571A3 (en) Identification of targets and development of reagents for testing and molecular imaging of human disease
WO2006042237A3 (en) B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
WO2007028162A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
DE602007011566D1 (en) Ankheit
WO2004044218A3 (en) Methods and materials for examining pathways associated with glioblastoma progression
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2007114986A3 (en) Cooperative probes and methods of using them
EP2589961A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2006121710A3 (en) Bladder cancer biomarkers and uses thereof
WO2006123955A3 (en) Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
WO2007117330A3 (en) Latent protein c assays and their uses for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2006092610A3 (en) Markers for melanoma
WO2007132120A3 (en) Procedure and methods for detecting alzheimer's disease
EP2535718A3 (en) Methods for early diagnosis of kidney disease
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06738585

Country of ref document: EP

Kind code of ref document: A2